Trial Profile

A Phase 2 Study of Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 22 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Radium 223 chloride (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Therapeutic Use
Acronyms RROPE

Most Recent Events

01 May 2026 Primary endpoint has been met. (Count of Participants Requiring Androgen Deprivation Therapy (ADT) Use at 15 Months)
01 May 2026 Results demonstrating tolerability of the therapy, preserves quality of life (QoL), and can be leading to undetectable PSA levels at 2 years were published in the International Journal of Radiation Oncology, Biology, Physics
07 Feb 2024 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com